NCT02067793已完成2 期
Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder
Naurex, Inc, an affiliate of Allergan plc12 个研究点 分布在 1 个国家目标入组 151 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 151
- 试验地点
- 12
- 主要终点
- To evaluate the mean change from baseline in Hamilton Depression Rating Scale 17 (HDRS-17) score for each NRX-1074 dose group versus the placebo group's mean change
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
详细描述
NRX-1074 is a N-methyl-D-aspartate (NMDA) receptor functional partial agonist with efficacy in animal models of affective disorders including major depressive disorder. The purpose of this study is to evaluate efficacy and safety of NRX-1074 at dose levels that are predicted by comparison of human and animal pharmacokinetics to be efficacious.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects
- •Aged 18 to 65 years
- •Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD)
- •Current episode has lasted ≥ 8 weeks before Screening
- •HDRS-17 score ≥ 21 before beginning the washout of all current antidepressant agents and/or adjuvant agents
- •HDRS-17 score ≥ 21 at Baseline (after 14 days of washout of current antidepressant agents)
- •Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal
- •Male subjects and their female sexual partner should use an acceptable method of birth control during the study
- •Clinical laboratory values < 2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor
- •Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments
- •Based on both the investigator and Naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes are permitted
排除标准
- •Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD
- •A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
- •Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis
- •Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures or strokes
- •Currently hospitalized or residing in an in-patient facility during the study participation
- •Substance abuse within the last 12 months, including greater than or equal to 5 units of alcohol per day where 1 unit = 1/2 pint of beer, 1 glass of wine, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator
- •Allergy or intolerance to current antidepressant or other current medications
- •Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial
- •Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent that in the opinion of the investigator is being abused
- •Have received electroconvulsive therapy, transcranial magnetic stimulation (TMS), or vagal nerve stimulation (VNS) for the current depressive episode
- •Post current (past 6 months) suicide risk based on administration of the C-SSRS and the investigator's clinical judgment
- •Human immunodeficiency virus (HIV) infection (based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease
- •Females or female partners of male subjects who are currently pregnant or planning to become pregnant during the course of the study. Women who are breastfeeding
- •Currently taking prescription (psychiatric treatments, antidepressant treatments) or over-the-counter medications including herbal therapies to treat their MDD or conditions secondary to their period following study drug dosing. Dextromethorphan or tramadol since these are serotonin uptake inhibitors.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
NRX-1074 1 mg
Experimental
NRX-1074 1 mg, intravenous
干预措施: NRX-1074 1 mg (Drug)
NRX-1074 5 mg
Experimental
NRX-1074 5 mg, intravenous
干预措施: NRX-1074 5 mg (Drug)
NRX-1074 10 mg
Experimental
NRX-1074 10 mg, intravenous
干预措施: NRX-1074 10 mg (Drug)
结局指标
主要结局
To evaluate the mean change from baseline in Hamilton Depression Rating Scale 17 (HDRS-17) score for each NRX-1074 dose group versus the placebo group's mean change
时间窗: Day 1, Day 3, Day 7, Day 14
Change in Hamilton Depression Rating Scale HDRS-17
次要结局
- Change in Clinician Administered Dissociative States Scale (CADSS)(Day 1)
- Change in Columbia-Suicide Severity Rating Scale (C-SSRS)(Day 1)
- Change in Brief Psychiatric Rating Scale positive symptoms (BPRS+) scale(Day 1)
研究者
研究点 (12)
Loading locations...
相似试验
撤回
2 期
NRX-1074 in Early Course SchizophreniaSchizophreniaNCT02603458NYU Langone Health
已完成
3 期
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Attention Deficit Disorders With HyperactivityAttention Deficit Hyperactivity DisordersAttention Deficit Hyperactivity DisorderNCT00334880New River Pharmaceuticals420
已完成
2 期
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate CancerProstate CancerNCT01620515Nymox Corporation141
已完成
1 期
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult VolunteersBacterial InfectionsNCT02955459Venatorx Pharmaceuticals, Inc.84
已完成
2 期
A Study of RX-10045 in the Treatment of Dry Eye DiseaseDry Eye SyndromeNCT01675570C.T. Development America, Inc.150